Adding topotecan to standard treatment for ovarian cancer does not improve progression-free survival
Tuesday, October 12, 2010 - 04:30
in Health & Medicine
Adding topotecan to carboplatin plus paclitaxel, the standard treatment for ovarian cancer, does not improve progression-free survival in patients and leads to greater toxicity, according to a study published online October 11 in the Journal of the National Cancer Institute...